Michael Silvey
Pediatric Hematology-Oncology · Kansas City, MONPI 1578747994
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (42.7%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Genentech USA, Inc. accounts for 68.3% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2019 at $36,416 and has fallen 70.0% since, to $10,924 in 2025. Among pediatric hematology-oncology clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 140 payments — averaging $885.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$85K
- Sanofi$30K
- HEMA Biologics, LLC$6K
- Bioverativ Therapeutics Inc.$3K
- Genentech, Inc.$333
- Novo Nordisk$159
- plus $360 from 6 others
Across 902 payments — averaging $145.11 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$99K
- Pfizer$32K
What the payments were for
- Consulting fees$52,14642%
- Speaking & faculty fees$53,00043%
- Travel & lodging$12,48310%
- Food & beverage$6,3615%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 85 | $84,631 |
| Sanofi | 39 | $29,549 |
| HEMA Biologics, LLC | 2 | $6,000 |
| Bioverativ Therapeutics Inc. | 1 | $2,958 |
| Genentech, Inc. | 4 | $333 |
| Novo Nordisk | 2 | $159 |
| Octapharma USA, Inc. | 1 | $107 |
| Shire North American Group Inc | 1 | $81 |
| Kedrion Biopharma Inc. | 1 | $73 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $58 |
| Pfizer | 1 | $21 |
| Novartis | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$123,989 in reported general payments places this provider in the 95th percentile of 78 pediatric hematology-oncology providers in Missouri.
See all pediatric hematology-oncology providers in Missouri →
Other pediatric hematology-oncology in Kansas City
- Lauren AmosKansas City$109K
- Ibrahim AhmedKansas City$79K
- Erin GuestKansas City$21K
- Shannon CarpenterKansas City$19K
- Gerald WoodsKansas City$11K
- Brian WicklundKansas City$9K
- Keith AugustKansas City$7K
- Terrie FlattKansas City$5K
- Jignesh DalalKansas City$4K
- Sara McElroyKansas City$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.